Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

Intra-Cellular recently guided to at least $5 billion in peak Caplyta sales. Intra-Cellular’s stock was trading at $127.48, up $32.61, or 34%. J&J’s stock (NYSE:JNJ) was selling for $143.39, up $1.34.

An F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent details new cannabinoid CB2 receptor modulators reported to be useful for the treatment of neuropathic pain, asthma, osteoporosis, ...

Quanterix Corp. plans to merge with Akoya Biosciences Inc., in an all-stock transaction that both companies hope will bolster ...

Canary Cure Therapeutics (Canary Global Inc.) has released preclinical results for its lead candidate, CCT-217, an siRNA ...

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

The U.S. FDA posted a draft guidance that would revisit a 2014 final guidance on sex-specific data drawn from medical device clinical trials, expanding the scope to include considerations of gender.

Insilico Medicine Inc. nabbed a potential $550 million-plus deal with Menarini Group’s Stemline Therapeutics Inc. for an unnamed preclinical small-molecule drug targeting solid tumors, adding to a ...

Joining the dealmaking spree to kick off the 2025 J.P. Morgan Healthcare Conference, Eli Lilly and Co. announced it was picking up an early clinical-stage PI3Kα inhibitor program from Scorpion ...

Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to ...

Shares of Phio Pharmaceuticals Corp. soared 291% Jan. 13 on news that two patients with cutaneous squamous cell carcinoma had a complete response following treatment with the company’s Intasyl siRNA ...